TY - JOUR T1 - AN EVALUATION OF EDUCATIONAL INSTITUTIONS SAFE REOPENING STRATEGIES FOR IN-PERSON CLASSES AMID THE COVID-19 PANDEMIC JF - medRxiv DO - 10.1101/2020.09.04.20188680 SP - 2020.09.04.20188680 AU - Ujjal Kumar Mukherjee AU - Subhonmesh Bose AU - Anton Ivanov AU - Sebastian Souyris AU - Sridhar Seshadri AU - Padmavati Sridhar AU - Ronald Watkins AU - Yuqian Xu Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/08/2020.09.04.20188680.abstract N2 - Research Context Can educational institutions open up safely amid COVID-19? We build an epidemiological model to investigate the strategies necessary for institutions to safely reopen. The four measures that are most relevant for in-person opening are: (i) wide-spread rapid testing, possibly saliva-based, (ii) enforcement of mask-wearing,(iii) social distancing, and (iv) contact tracing.Research Design Using an analytical setup, we theoretically demonstrate that institutions need to test at a relatively high level (e.g., at least once every week for all individuals) in the initial phases of reopening. Guided by the analytical setup, we derive insights from an agent-based simulation. Contact tracing is relatively more important when the positivity rate from random testing is relatively low, which is likely during the initial phases. An adaptive testing strategy based on positivity rates can help institutions optimally manage the costs and risks of reopening. Finally, to demonstrate the strategies in practice, we provide empirical estimates of some of the educational institutions opening up experience and comment on mitigation strategies. Empirically, we characterize the role of testing using data from the SHIELD program at the University of Illinois at Urbana Champaign (UIUC).Results We show that increasing the testing levels from 0.2 per capita per day to 0.3 per capita per day can reduce the infectivity from 0.25 to 0.01, with an average slope of the infectivity to the testing curve being 0.35 in this range. We also cross-validate the results with data from a large number of universities in the United States, and show that institutions with higher levels of testing are associated with lower infections. The estimated marginal effect of increasing testing levels by 1% per capita per day across universities can reduce the positivity by an average of 0.0228% with a 99% confidence interval of [0.0209%-0.0253%]. We also provide an estimate of the locational effects of institutions on mitigation strategies. We estimate from data on 228 different universities across the United States that an increase of infection rate at the county where a university is located by 1% has the potential to increase the institutional infection rate by an average of 0.14% with a 99% confidence interval of [0.032% – 0.248%] across all universities. This indicates that universities are not closed systems, rather they are open systems subject to external influence, and the extent of external influence potential is an important consideration for opening up of universities.Contributions This paper contributes to the nascent literature on combating the COVID-19 pandemic and is especially relevant for large organizations. This work is motivated and guided by the SHIELD program of UIUC. We provide important policy pointers for the reopening of universities.Competing Interest StatementThe authors have declared no competing interest.Funding Statementc3.ai COVID-19 research funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:None required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe simulation codes will be made available on request. ER -